In September 2004, the members of the International Committee of Medical Journal Editors (ICMJE) published a joint editorial aimed at promoting registration of all clinical trials. We stated that we will consider a trial for publication only if it has been registered before the enrollment of the first patient. This policy applies to trials that start recruiting on or after July 1, 2005. Because many ongoing trials were not registered at inception, we will consider for publication ongoing trials that are registered before September 13, 2005. Our goal then and now is to foster a comprehensive, publicly available database of clinical trials. A complete registry of trials would be a fitting way to thank the thousands of participants who have placed themselves at risk by volunteering for clinical trials. They deserve to know that the information that accrues from their altruism is part of the public record, where it is available to guide decisions about patient care, and deserve to know that decisions about their care rest on all of the evidence, not just the trials that authors decided to report and that journal editors decided to publish.

We are not alone in pursuing this goal. The World Health Organization (WHO), through meetings in New York, Mexico City, and Geneva, has brought us close to the goal of a single worldwide standard for the information that trial authors must disclose. Around the world, governments are beginning to legislate mandatory disclosure of all trials. For example, among the bodies considering new legislation is the U. S. Congress, where the proposed Fair Access to Clinical Trials (FACT) Act would expand the current mandate for registration of clinical trials. Many other journals have adopted our policy of requiring trial registration. These initiatives show that trial registration has become a public issue. But, as our deadline for registration approaches, trial authors and sponsors want to be sure that they understand our requirements, so that reports of their research will be eligible for editorial review. The purpose of this joint and simultaneously published editorial is to answer questions about the ICMJE initiative and to bring our position into harmony with that of others who are working toward the same end.

Our definition of a clinical trial remains essentially the same as in our September 2004 editorial: "Any research project that prospectively assigns human subjects to intervention and comparison groups to study the cause-and-effect relationship between a medical intervention and a health outcome." By "medical intervention" we mean any intervention used to modify a health outcome. This definition includes drugs, surgical procedures, devices, behavioral treatments, process-of-care changes, and the like. We update our 2004 editorial to state that a trial must have at least one prospectively assigned concurrent control or comparison group in order to trigger the requirement for registration.

Among the trials that meet this definition, which need to be registered? The ICMJE wants to ensure public access to all "clinically directive" trials -- trials that test a clinical hypothesis about health

*Available from website: http://www.icmje.org/clin_trialup.htm
We recognize that requiring public registration of trials whose prespecified goal is to investigate the biology of disease or to direct further research might slow the forces that drive innovation. Therefore, each journal editor will decide on a case-by-case basis about reviewing unregistered trials in this category. Authors whose trial is unregistered will have to convince the editor that they had a sound rationale when they decided not to register their trial. The ICMJE will maintain this policy for the next two years. We will then review our experience.

Our September 2004 editorial specified the information that we would require for trial registration. Attendees at a recent meeting of the

---

**Table 1 - Minimal Registration Data Set.**

<table>
<thead>
<tr>
<th>Item</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Unique trial number</td>
<td>The unique trial number will be established by the primary registering entity (the registry).</td>
</tr>
<tr>
<td>2. Trial registration date</td>
<td>The date of registration will be established by the primary registering entity.</td>
</tr>
<tr>
<td>3. Secondary IDs</td>
<td>May be assigned by sponsors or other interested parties (there may be none).</td>
</tr>
<tr>
<td>4. Funding source(s)</td>
<td>Name of the organization(s) that provided funding for the study.</td>
</tr>
<tr>
<td>5. Primary sponsor</td>
<td>The main entity responsible for performing the research.</td>
</tr>
<tr>
<td>6. Secondary sponsor(s)</td>
<td>The secondary entities, if any, responsible for performing the research.</td>
</tr>
<tr>
<td>7. Responsible contact person</td>
<td>Public contact person for the trial, for patients interested in participating.</td>
</tr>
<tr>
<td>8. Research contact person</td>
<td>Person to contact for scientific inquiries about the trial.</td>
</tr>
<tr>
<td>9. Title of the study</td>
<td>Brief title chosen by the research group (can be omitted if the researchers wish).</td>
</tr>
<tr>
<td>10. Official scientific title of the study</td>
<td>This title must include the name of the intervention, the condition being studied, and the outcome (e.g., The International Study of Digoxin and Death from Congestive Heart Failure).</td>
</tr>
<tr>
<td>11. Research ethics review</td>
<td>Has the study at the time of registration received appropriate ethics committee approval (yes/no)? (It is assumed that all registered trials will be approved by an ethics board before commencing.)</td>
</tr>
<tr>
<td>12. Condition</td>
<td>The medical condition being studied (e.g., asthma, myocardial infarction, depression).</td>
</tr>
<tr>
<td>13. Intervention(s)</td>
<td>A description of the study and comparison/control intervention(s) (For a drug or other product registered for public sale anywhere in the world, this is the generic name; for an unregistered drug the generic name or company serial number is acceptable). The duration of the intervention(s) must be specified.</td>
</tr>
<tr>
<td>14. Key inclusion and exclusion criteria</td>
<td>Key patient characteristics that determine eligibility for participation in the study.</td>
</tr>
<tr>
<td>15. Study type</td>
<td>Database should provide drop-down lists for selection. This would include choices for randomized vs. non-randomized, type of masking (e.g., double-blind, single-blind), type of controls (e.g., placebo, active), and group assignment, (e.g., parallel, crossover, factorial).</td>
</tr>
<tr>
<td>16. Anticipated trial start date</td>
<td>Estimated enrollment date of the first participant.</td>
</tr>
<tr>
<td>17. Target sample size</td>
<td>The total number of subjects the investigators plan to enroll before closing the trial to new participants.</td>
</tr>
<tr>
<td>18. Recruitment status</td>
<td>Is this information available (yes/no) (If yes, link to information).</td>
</tr>
<tr>
<td>19. Primary outcome</td>
<td>The primary outcome that the study was designed to evaluate Description should include the time at which the outcome is measured (e.g., blood pressure at 12 months)</td>
</tr>
<tr>
<td>20. Key secondary outcomes</td>
<td>The secondary outcomes specified in the protocol. Description should include time of measurement (e.g., creatinine clearance at 6 months).</td>
</tr>
</tbody>
</table>

*The data fields were specified at a meeting convened by the WHO in April 2004; the explanatory comments are largely from the ICMJE.
The purpose of a clinical trials registry is to promote the public good by ensuring that everyone can find key information about every clinical trial whose principal aim is to shape medical decision-making. We will do what we can to help reach this goal. We urge all parties to register new and ongoing clinical trials. If in doubt about whether a trial is "clinically directive," register it. Don't use meaningless phrases to describe key information. Every trial participant and every investigator should be asking, "Is this clinical trial fully registered?"

Catherine D, De Angelis, MD, MPH
Editor-in-Chief, JAMA

Jeffrey M. Drazen, MD
Editor-in-Chief, New England Journal of Medicine

Professor Frank A. Frizelle, MBChB, MMedSc, FRACS
Editor, The New Zealand Medical Journal

Charlotte Haug, MD, PhD, MSc
Editor-in-Chief, Norwegian Medical Journal

John Hoey, MD
Editor, CMAJ

Richard Horton, FRCP
Editor, The Lancet

Sheldon Kotzin, MLS
Executive Editor, MEDLINE
National Library of Medicine

Christine Laine, MD, MPH
Senior Deputy Editor, Annals of Internal Medicine

Ana Marusic, MD, PhD
Editor, Croatian Medical Journal

A. John P.M. Overbeke, MD, PhD
Executive Editor, Nederlands Tijdschrift voor Geneeskunde (Dutch Journal of Medicine)

Torben V. Schroeder, MD, DMSc
Editor, Journal of the Danish Medical Association

Harold C. Sox, MD
Editor, Annals of Internal Medicine

Martin B. Van Der Weyden, MD
Editor, The Medical Journal of Australia

References

Commentary

The Ottawa Statement. International registration of protocol information and results from human trials of health related interventions

Zbys Fedorowicz, BDS, LDS RCS (Eng), Amani A. Al-Hajeri, MD.

The impact of recent events, with the selective reporting of the results of clinical trials has led to an erosion of public and academic confidence in the publication of clinical trials, and which has motivated renewed calls for increased control of trial registration. The publication of these systematic reviews on the effects of selective serotonin reuptake inhibitors for childhood depression appears to have galvanized individual stakeholders into action. Not least of all their highly publicized sequelae have emphasized the dangers of incomplete disclosure of trial results, heightened the significance of trial registration, and recognized the increased urgency for a globally acceptable method of trial registration. Significantly, there has been a positive response from leading journal editors, the International Committee of Medical Journal Editors (ICMJE), medical associations and industry in perhaps recognizing the contribution that would be made to social good if the totality of research, some of which remains ‘buried’, was made available to the global community.

An open meeting in Ottawa on the 4th of October 2004 hosted by the Canadian Institutes of Health, and a follow up meeting at the Cochrane Colloquium in Ottawa assembled a group of individuals interested in fostering international consensus on trial registration. The vision held by the contributors was to develop a protocol that may shape the transition to a new paradigm of health research based on transparency, full disclosure, and collaboration. The results of these and subsequent consultations led to the development of the Ottawa Statement, which has as its main aim the establishment of internationally recognized principles for the registration of clinical trials. The full statement is available at http://ottawagroup.ohri.ca/statement.html, but here we highlight the rationale and some of its key principles.

Rationale for registration of clinical trials. 1) Ethical. Respect the investigator-participant covenant to contribute to biomedical knowledge by making trial methods and results public. Provide global open access to information. Reduce unnecessary duplication of invested research resources through awareness of existing trials. Assure accountability with regard to global standards for ethical research. Enable monitoring of adherence to ethical principles and process. 2) Scientific. Increase the reliability and availability of evidence upon which healthcare decisions are based. Improve trial participation. Increase opportunities for collaboration. Ensure transparency of trial design and methods. Provide open review of protocols to improve trial quality, and the refining of the methods of trial conduct. Provide means for identification and prevention of biased under or over-reporting of research. Accelerate knowledge creation.

Outline of the Ottawa Statement (Part 1). Key principles. a) Registering all types of trials. "Protocol information and results from all trials related to health or healthcare regardless of topic, design, outcomes, or market status of interventions examined should be registered and publicly available." b) Timing of public release of protocol information. "The public should have cost-free access to the Unique ID, minimum protocol items, and consent forms prior to the participant enrollment. Registered amendments should be made publicly available as they occur." c) Registering unpublished results. "At a minimum, results for outcomes and analyses specified in the protocol (as approved by the institutional review boards/ independent ethics committees), as well as data on harms, should be registered regardless of whether or not they are published."

Summary of the principles. Sponsors, principal investigators, journals, and ethics committees all have certain responsibilities to ensure comprehensive registration of trials. The mandatory registration of all trials will have 3 components: a) Obtaining an internationally unique identification number (Unique ID), b) Registering the original protocol along with subsequent amendments, and c) Registering the trial results.

The Ottawa group currently consists of over 80 individuals, representing a number of research organizations and individuals from 5 continents, with an interest in ensuring that health research is based on transparency, full disclosure and collaboration, who will continue to consult broadly regarding the most effective and practical ways to enact these principles in a coordinated fashion worldwide. Additional initiatives are being driven by the World Health Organization, which has assembled a group to guide the development of global trial registration and has used an earlier draft of the statement to shape its plans. The Cochrane Collaboration has also endorsed this statement, and through its network is encouraging further dissemination of the principles of the Ottawa Statement. The members of the Ottawa group are encouraging other stakeholders to do the same and to thereby contribute to public discussion of this important issue.
Summary points. Registration and early public release of accurate information regarding all trials is necessary to fulfill an ethical obligation to participants. Although, protection of commercial and other interests is important, the social contract with participants should take precedence. All trial results should be registered and publicly available, along with sufficient protocol information to enable critical assessment of their validity.

Implications for clinical trials in the region. There are a number of questions that need to be asked if we are to ensure that clinical trials conducted in the region comprehensively address this issue. Should there be a registry established in the region? Who should be responsible for maintaining it? What mechanisms are available for regional editors to come to an agreement regarding mandatory registration of all clinical trials conducted in the region? What could be the role of WHO, Eastern Mediterranean Regional Office, Eastern Mediterranean Association of Medical Editors, and the regional entity of the Cochrane Collaboration, in this initiative?

Received 3rd July 2005. Accepted for publication in final form 11th September 2005.

References